<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431798</article-id><article-id pub-id-type="pmcid-ver">PMC12431798.1</article-id><article-id pub-id-type="pmcaid">12431798</article-id><article-id pub-id-type="pmcaiid">12431798</article-id><article-id pub-id-type="doi">10.7759/cureus.90020</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Hematology</subject></subj-group><subj-group><subject>Oncology</subject></subj-group></article-categories><title-group><article-title>Hyperferritinemia as a Clue to Neuroendocrine Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Chao</surname><given-names initials="ES">Eugene S</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yoshikawa</surname><given-names initials="G">Gene</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Qing</surname><given-names initials="X">Xin</given-names></name><xref rid="aff-3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="C">Charity</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Internal Medicine, Harbor University of California Los Angeles Medical Center, Torrance, USA </aff><aff id="aff-2">
<label>2</label>
Hematology Oncology, Harbor University of California Los Angeles Medical Center, Torrance, USA </aff><aff id="aff-3">
<label>3</label>
Pathology, Harbor University of California Los Angeles Medical Center, Torrance, USA </aff><author-notes><corresp id="cor1">
Eugene S. Chao <email>eugeneschao@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>13</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>8</month><year>2025</year></pub-date><volume>17</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">494304</issue-id><elocation-id>e90020</elocation-id><history><date date-type="accepted"><day>12</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>13</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025, Chao et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Chao et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cureus-0017-00000090020.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cureus.com/articles/382293-hyperferritinemia-as-a-clue-to-neuroendocrine-carcinoma">This article is available from https://cureus.com/articles/382293-hyperferritinemia-as-a-clue-to-neuroendocrine-carcinoma</self-uri><abstract><p>Ferritin is the protein that serves as the main mechanism for iron storage. It can also be an acute-phase reactant, which may rise in response to inflammation, infection, injury, autoimmune disease, or malignancy. Therefore, when evaluating ferritin levels, it is important to consider both iron storage and potential underlying conditions that could cause hyperferritinemia. We report a case of an elderly man in his late 80s who had elevated ferritin levels for years before ultimately being diagnosed with metastatic neuroendocrine carcinoma. The initial diagnosis was suspected to be due to iron overload from iatrogenic causes, but despite discontinuation of iron supplementation, the patient continued to have hyperferritinemia. Broad differential diagnoses were considered, including hereditary hemochromatosis, sideroblastic anemia, thalassemia, viral infection, hereditary hyperferritinemia, myelodysplastic syndromes with ineffective iron regulation, hemophagocytic lymphohistiocytosis, and other autoimmune phenomena. However, workup was negative. Ultimately, bone marrow biopsy was performed, which revealed poorly differentiated metastatic carcinoma with neuroendocrine differentiation.</p></abstract><kwd-group kwd-group-type="author"><kwd>anemia workup</kwd><kwd>hyperferritinemia</kwd><kwd>neuroendocrine carcinoma of prostate</kwd><kwd>neuroendocrine differentiation</kwd><kwd>poorly differentiated metastatic carcinoma</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ferritin is the protein responsible for iron storage, forming multimeric assemblies with crystalline iron cores [<xref rid="REF1" ref-type="bibr">1</xref>]. Clinically, abnormal ferritin often reflects disturbances in iron homeostasis or metabolism. Elevated ferritin can be observed in iron-overloaded states such as hereditary hemochromatosis and transfusion iron overload [<xref rid="REF2" ref-type="bibr">2</xref>]. Ferritin is also an acute-phase reactant, rising in response to inflammation, bacterial and viral infection [<xref rid="REF3" ref-type="bibr">3</xref>], injury, autoimmune disease, and malignancy [<xref rid="REF4" ref-type="bibr">4</xref>]. Due to the extensive range of associated conditions, the differential diagnosis should remain broad, and further workup should be performed.&#160;</p><p>Prior studies have observed a correlation between increased ferritin concentrations and diverse malignant conditions. As early as the 1980s, a study of 21,513 Chinese male government workers in Taiwan showed that the relative risk of all cancer death for men with a serum ferritin level of 200ng/mL was 2.9 compared to men with a serum ferritin level of 20ng/mL [<xref rid="REF5" ref-type="bibr">5</xref>]. Later studies have shown that various malignancies, including neuroendocrine neoplasms, are associated with elevated ferritin levels [<xref rid="REF4" ref-type="bibr">4</xref>]. The light chain of the ferritin molecule has been known to be upregulated under hypoxic conditions, which are commonly observed in malignancy. Specifically, the direct binding of hypoxia-inducible factor 1-alpha (HIF 1&#945;) to the hypoxia response element (HRE-3) region of the ferritin light chain promoter has been implicated in increased transcription activity of ferritin in the setting of tumor growth and metastasis [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>Neuroendocrine neoplasms are a heterogeneous group of malignancies with cells containing both &#8220;neuro&#8221; and &#8220;endocrine&#8221; properties [<xref rid="REF7" ref-type="bibr">7</xref>]. The &#8220;neuro&#8221; property derives from the dense-core granules also present in serotonergic neurons [<xref rid="REF8" ref-type="bibr">8</xref>], whereas the &#8220;endocrine&#8221; property derives from the synthesis and secretion of monoamines [<xref rid="REF9" ref-type="bibr">9</xref>]. Neuroendocrine tumors can arise from various endocrine glands, including the pituitary, parathyroid, adrenals, the islets of thyroid and pancreas, and from cells lying between exocrine glands such as gastroenteropancreatic and respiratory tracts. There are approximately 100,000 cases of neuroendocrine tumors in the US [<xref rid="REF9" ref-type="bibr">9</xref>], making it a somewhat rare diagnosis.&#160;Here, we present a challenging diagnostic case of a patient with elevated ferritin levels for years, where broad differential diagnoses were considered, ultimately leading to an unexpected diagnosis of metastatic neuroendocrine carcinoma (NEC).</p></sec><sec sec-type="cases"><title>Case presentation</title><p>We present a case of an elderly man in his late 80s with a past medical history notable for hypertension, hypothyroidism, benign prostatic hyperplasia, bilateral cataracts, and hearing loss, who was referred to hematology for suspected iron overload.</p><p>Starting in 2017, and possibly before that, the patient was noted to have macrocytic anemia with hemoglobin (Hgb) levels between 12 and 13 (reference range:&#160;13.5-16.5 g/dL) and a mean corpuscular volume (MCV) in the low 100s (reference range:&#160;82.0-97.0 fL).&#160;Despite these findings, the macrocytic anemia had been stable, and the patient remained asymptomatic. Reportedly, the patient had undergone a colonoscopy in the past without any apparent abnormalities; however, he had no documentation of the findings.&#160;Given persistent anemia, oral iron supplementation was empirically initiated by the patient&#8217;s primary care provider in mid-2020.&#160;</p><p>In mid-2021, the ferritin level was found to be elevated to 1718. By early 2022, iron saturation was elevated to 67%, and total iron-binding capacity (TIBC) was low at 240 (reference range: 261-478 mcg/dL). These findings raised concerns for iron overload. Vitamin B12, folate, and TSH levels were all within normal limits. On initial hematology evaluation, the patient endorsed generalized fatigue for the past year without other symptoms such as bruising, bleeding, abdominal pain, headaches, or tinnitus. The physical exam was grossly benign. It was thought that the patient&#8217;s hyperferritinemia was likely due to ferrous sulfate administration. The patient was advised to discontinue ferrous sulfate tablets and reduce wine consumption, as it was thought this could have contributed to macrocytosis. Initially, ferritin levels trended down to 1420 but subsequently rose to 1595 and then to 1824 by early 2024 despite discontinuation of ferrous sulfate. Iron saturation also trended down but then rose to 88% by early 2024. During that period, he had stable macrocytic anemia, with Hgb in the 11 to 13 range and MCV in the 101 to 103 range. Throughout this period, the patient remained asymptomatic, except for stable generalized fatigue, with continued physical exam findings.</p><p>Given the persistently elevated ferritin and iron levels despite stopping iron supplementation, hereditary hemochromatosis was considered. Tests for hemochromatosis (HFE) mutation, including C282Y and H63D, were ordered, yielding negative results. However, an abdominal MRI performed in mid-2024 did suggest hepatic iron deposition. Other possible diagnoses, such as sideroblastic anemia, thalassemia (thought to be less likely given low RBC count and macrocytosis), viral infection, hereditary hyperferritinemia, myelodysplastic syndromes (MDS) with ineffective iron regulation, hemophagocytic lymphohistiocytosis (HLH), and other autoimmune phenomena, were considered but seemed less likely (Table <xref rid="TAB1" ref-type="table">1</xref>). Typically, iron overload is a result of anemia of chronic disease [<xref rid="REF10" ref-type="bibr">10</xref>] or hemolytic anemia [<xref rid="REF11" ref-type="bibr">11</xref>]. Therefore, patient&#8217;s macrocytic anemia was thought to be unrelated to iron overload. Given concern for a possible primary bone marrow process, bone marrow biopsy was recommended in late 2023, but the patient declined. Patient&#8217;s ferritin continued to up-trend, rapidly reaching levels in the 5000 range (Figure <xref rid="FIG1" ref-type="fig">1</xref>).</p><table-wrap position="float" id="TAB1" orientation="portrait"><label>Table 1</label><caption><title>Additional Lab Studies</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Lab</td><td rowspan="1" colspan="1">Value</td><td rowspan="1" colspan="1">Reference Range</td></tr><tr><td rowspan="1" colspan="1">Hepatitis Bs Ag</td><td rowspan="1" colspan="1">Nonreactive</td><td rowspan="1" colspan="1">Nonreactive</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hepatitis Bs Ab</td><td rowspan="1" colspan="1">65.97 mIU/mL</td><td rowspan="1" colspan="1">&gt;=12.00 mIU/mL</td></tr><tr><td rowspan="1" colspan="1">Hepatitis C Ab</td><td rowspan="1" colspan="1">Nonreactive</td><td rowspan="1" colspan="1">Nonreactive</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">HIV screen</td><td rowspan="1" colspan="1">Nonreactive</td><td rowspan="1" colspan="1">Nonreactive</td></tr><tr><td rowspan="1" colspan="1">C282Y HFE mutation</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">H63D HFE mutation</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">Copper level</td><td rowspan="1" colspan="1">85 mcg/dL</td><td rowspan="1" colspan="1">70-175 mcg/dL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Zinc level</td><td rowspan="1" colspan="1">57 mcg/dL</td><td rowspan="1" colspan="1">60-130 mcg/dL</td></tr><tr><td rowspan="1" colspan="1">Vitamin B1</td><td rowspan="1" colspan="1">171 nmol/L</td><td rowspan="1" colspan="1">78-185 nmol/L</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Triglyceride</td><td rowspan="1" colspan="1">86 mg/dL</td><td rowspan="1" colspan="1">&lt;149 mg/dL</td></tr><tr><td rowspan="1" colspan="1">Vitamin B12</td><td rowspan="1" colspan="1">792 pg/mL</td><td rowspan="1" colspan="1">180-914 pg/mL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Folate</td><td rowspan="1" colspan="1">35.1 ng/mL</td><td rowspan="1" colspan="1">&gt;=5.9 ng/mL</td></tr><tr><td rowspan="1" colspan="1">TSH</td><td rowspan="1" colspan="1">1.948 uIU/mL</td><td rowspan="1" colspan="1">0.350-4.940 uIU/mL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">ESR</td><td rowspan="1" colspan="1">23 mm/hr</td><td rowspan="1" colspan="1">0-22 mm/hr</td></tr><tr><td rowspan="1" colspan="1">CRP</td><td rowspan="1" colspan="1">0.16 mg/dL</td><td rowspan="1" colspan="1">0.00-0.74 mg/dL</td></tr></tbody></table></table-wrap><fig position="anchor" fig-type="figure" id="FIG1" orientation="portrait"><label>Figure 1</label><caption><title>Timeline of Patient&#8217;s Hemoglobin, MCV, Iron, Iron Saturation, and Ferritin Levels</title><p>As shown in (e),&#160;ferritin levels continued to rise, from 1,718 ng/mL in mid-2021 to greater than 5,000 ng/mL by early 2024, despite cessation of iron supplementation in October 2022. (a) Hemoglobin level. (b) MCV. (c) Iron level. (d) Iron saturation. (e) Ferritin level</p><p>MCV: Mean&#160;corpuscular volume</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000090020-i01.jpg"/></fig><p>By mid-2024, the patient ultimately agreed to a bone marrow biopsy for further evaluation of persistent hyperferritinemia and macrocytic anemia.&#160;Bone marrow aspirate and biopsy revealed metastatic carcinoma (Figures <xref rid="FIG2" ref-type="fig">2a</xref>, <xref rid="FIG2" ref-type="fig">2b</xref>) positive for pancytokeratin AE1/AE3&#160;with adequate iron storage (Figure <xref rid="FIG2" ref-type="fig">2c</xref>), and negative for vimentin, CK7, and CK20 (Figure <xref rid="FIG2" ref-type="fig">2d</xref>).&#160;The bone marrow aspirate smears were largely hemodilute, showing predominantly peripheral blood with no bone marrow spicules. The bone marrow biopsy demonstrated a marked replacement of normal hematopoietic elements by sheets and clusters of malignant cells, accompanied by surrounding fibrosis (Figures <xref rid="FIG2" ref-type="fig">2a</xref>, <xref rid="FIG2" ref-type="fig">2b</xref>). Immunohistochemical stains revealed that the malignant cells were positive for pancytokeratin AE1/AE3, and negative for vimentin, CK7, and CK20 (Figure <xref rid="FIG2" ref-type="fig">2d</xref>). This immunohistochemical pattern can be seen in prostate adenocarcinoma, clear cell renal cell carcinoma, hepatocellular carcinoma, adrenal cortical carcinoma, small cell lung carcinoma, gastric adenocarcinoma, and others [<xref rid="REF12" ref-type="bibr">12</xref>,<xref rid="REF13" ref-type="bibr">13</xref>]. Additional stains showed tumor cells weakly positive for synaptophysin, negative for TTF-1, CDX-2, chromogranin, and inhibin&#160;but showed equivocal results for Hep-Parl, PSA, and PAX-8 (Figure <xref rid="FIG3" ref-type="fig">3</xref>). These findings suggested poorly differentiated metastatic carcinoma with neuroendocrine differentiation (NED) [<xref rid="REF12" ref-type="bibr">12</xref>,<xref rid="REF13" ref-type="bibr">13</xref>]. Given the bone marrow biopsy findings, computed tomography of the chest, abdomen, and pelvis did not identify any discrete or apparent mass. Other findings included a severely enlarged prostate and multiple foci of sclerosis involving the osseous structures of the pelvis. Given these findings, prostate cancer with NED was considered as an etiology. Further workup was recommended, but after extensive discussion, the patient and his family chose to defer further diagnostics, including prostate biopsy, PET/CT, and additional lab tests such as LDH, repeat PSA (4.4ng/mL in late 2017, 1.6ng/mL in mid-2022), and treatment with chemotherapeutic agents such as carboplatin and etoposide. The patient was subsequently referred for home hospice services and eventually passed away several weeks later.</p><fig position="anchor" fig-type="figure" id="FIG2" orientation="portrait"><label>Figure 2</label><caption><title>Bone Marrow Biopsy</title><p>(a, b) Bone marrow biopsy showing sheets and clusters of large malignant cells (yellow arrows) and fibrosis (black arrow)&#160;(Hematoxylin and eosin stain, original magnification, &#215; 100 (a), &#215; 200 (b)). (c) Iron: Prussian blue stain performed on the bone marrow clot section shows adequate stainable iron stores. (d) The malignant cells are positive for pancytokeratin AE1/AE3, and negative for vimentin (not shown), supporting the diagnosis of metastatic carcinoma (immunohistochemical stain).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000090020-i02.jpg"/></fig><fig position="anchor" fig-type="figure" id="FIG3" orientation="portrait"><label>Figure 3</label><caption><title>Further Immunohistochemical Stains Demonstrating Neuroendocrine Differentiation</title><p>The tumor cells are weakly positive for synaptophysin (a), and negative for chromogranin (not shown), vimentin (b), CK7 (c), and CK20 (d).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000090020-i03.jpg"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Ferritin is a non-specific biomarker that can be elevated in iron storage disturbances, inflammation, autoimmune diseases, or malignancy. For this patient, the initial differential diagnosis was suspected to be iron overload from iatrogenic causes. However, in the months after the discontinuation of iron supplementation, iron, as well as ferritin levels, continued to worsen. Despite these lab abnormalities, the patient endorsed generalized fatigue that had been stable, without additional symptoms, and physical exam remained grossly benign. These findings prompted us to broaden the differential diagnoses (Table <xref rid="TAB2" ref-type="table">2</xref>).</p><table-wrap position="float" id="TAB2" orientation="portrait"><label>Table 2</label><caption><title>Etiologies of Hyperferritinemia</title></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Etiology</td><td rowspan="1" colspan="1">Specific Causes/Examples</td></tr><tr><td rowspan="1" colspan="1">Iron Overload Syndromes</td><td rowspan="1" colspan="1">Hereditary hemochromatosis, secondary iron overload (chronic transfusions, thalassemia, myelodysplastic syndrome, sideroblastic anemia, sickle cell disease, pyruvate kinase deficiency)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Infection</td><td rowspan="1" colspan="1">Acute and chronic infections (bacterial, viral (e.g., hepatitis, HIV, EBV, CMV), fungal, parasitic (malaria, dengue))</td></tr><tr><td rowspan="1" colspan="1">Chronic Liver Disease</td><td rowspan="1" colspan="1">Alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis B/C, acute hepatitis, cirrhosis, porphyria cutanea tarda</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Renal Disease</td><td rowspan="1" colspan="1">Chronic kidney disease, nephrotic syndrome</td></tr><tr><td rowspan="1" colspan="1">Metabolic Syndrome</td><td rowspan="1" colspan="1">Obesity, diabetes mellitus, metabolic syndrome</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hereditary Hyperferritinemia without Iron Overload</td><td rowspan="1" colspan="1">Hereditary hyperferritinemia-cataract syndrome, ferroportin disease, aceruloplasminemia, atransferrinemia</td></tr><tr><td rowspan="1" colspan="1">Rheumatologic/Inflammatory</td><td rowspan="1" colspan="1">Adult-onset Still&#8217;s disease, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, macrophage activation syndrome, hemophagocytic lymphohistiocytosis (HLH)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Malignancy</td><td rowspan="1" colspan="1">Hematologic malignancies (leukemia, lymphoma, myelodysplastic syndrome), solid organ malignancies</td></tr><tr><td rowspan="1" colspan="1">Others</td><td rowspan="1" colspan="1">Iatrogenic (parenteral iron, iron supplements), repeated blood transfusions, severe tissue injury, rare genetic/metabolic disorders</td></tr></tbody></table></table-wrap><p>Primary iron storage disease, such as hereditary hemochromatosis, can directly lead to hyperferritinemia and was therefore considered first for this patient. However, tests for hemochromatosis&#160;mutation including C282Y and H63D were negative. Then, diseases of ineffective erythropoiesis and increased iron absorption leading to hyperferritinemia, such as sideroblastic anemia and thalassemia, were considered. However, these diseases were thought to be less likely, given low RBC count and macrocytosis. As an acute-phase reactant, hyperferritinemia can be observed in the setting of viral or bacterial infection. However, this patient lacked the signs, symptoms, and laboratory and imaging findings of infection, rendering them less likely. Due to immune-mediated ferritin stimulation by cytokines, autoimmune phenomena such as HLH&#160;were also considered. However, the patient lacked the constellation of findings associated with HLH.&#160;A diagnosis of HLH must meet five out of eight of the following criteria: fever, splenomegaly, cytopenias, hypertriglyceridemia, evidence of hemophagocytosis, low or absent natural killer cell activity, hyperferritinemia, and elevated soluble CD25 [<xref rid="REF14" ref-type="bibr">14</xref>]. In a 2013 retrospective study of 627 patients with ferritin levels above 1,000 in an academic center, malignancy was most often diagnosed (153/627 patients) as the cause of the elevated ferritin. This was followed by iron overload syndromes (136 patients) [<xref rid="REF15" ref-type="bibr">15</xref>]. Few diagnoses of HLH (six patients) and anemia of chronic inflammation (seven patients) were made, and in five patients, there was no clearly definable cause.</p><p>Hyperferritinemia can be observed in a variety of malignancies. A 2025 study screened an extensive dataset of 1.3 million patients with elevated ferritin values from the Israeli Maccabi Health Services, which showed a significant association between hyperferritinemia and a cancer diagnosis, with an odds ratio of 1.9 (95% confidence interval 1.71 - 2.15) [<xref rid="REF16" ref-type="bibr">16</xref>]. In myelodysplastic syndrome&#160;(MDS), ineffective iron regulation may lead to hyperferritinemia. In a 2008 study of 2,994 patients with de novo MDS, a ferritin level of greater than 1,000 ng/mL served as a surrogate for iron overload and was strongly associated (hazard ratio (HR) 52.4, P&lt;.0001) with decreased overall survival, as well as risk for acute myeloid leukemia (AML) transformation (HR 6.6, P&lt;.0001) [<xref rid="REF17" ref-type="bibr">17</xref>]. Similarly, hyperferritinemia can also be observed and serve as a prognostic factor in leukemias. In 2018, a Japanese multicenter retrospective study demonstrated that ferritin levels greater than 400 ng/mL had a negative event-free survival at 5 years (30% vs 40%; P=0.033) in AML patients [<xref rid="REF18" ref-type="bibr">18</xref>]. In both AML and acute lymphoblastic leukemia (ALL), patients require frequent transfusions, and ferritin is used as a surrogate for iron overload. In a 2024 study of children with AML and ALL in one cancer center in Poland, 41% of children had serum ferritin (SF) over 500 ng/mL, and 14% had SF over 1000 ng/mL at the time of diagnosis. After treatment, 80% of children had SF over 500 ng/mL, and 31% had SF over 1000 ng/mL, with a positive correlation between SF and units of blood transfused [<xref rid="REF19" ref-type="bibr">19</xref>]. In a 2021 prospective study of 29 breast cancer patients, when compared to a control of 59 healthy women, there was a positive correlation between ferritin levels and breast cancer (p = 0.083) [<xref rid="REF20" ref-type="bibr">20</xref>]. A 2022 meta-analysis of 12 retrospective studies on patients (1654 total) with lung cancer showed that pre-treatment hyperferritinemia was associated with worse overall survival [<xref rid="REF21" ref-type="bibr">21</xref>]. In GI malignancies, hyperferritinemia is observed in colorectal cancer [<xref rid="REF22" ref-type="bibr">22</xref>,<xref rid="REF23" ref-type="bibr">23</xref>], as well as hepatocellular carcinoma [<xref rid="REF24" ref-type="bibr">24</xref>,<xref rid="REF25" ref-type="bibr">25</xref>] patients. Across these GI studies, hyperferritinemia is shown to be associated with a worse prognosis. Lastly, hyperferritinemia is associated with disease-free survival and overall survival in a 2023 study of 367 patients with endometrial carcinoma [<xref rid="REF26" ref-type="bibr">26</xref>].</p><p>Neuroendocrine neoplasms have distinct pathologic features. In poorly differentiated NEC, cytology may show a dirty smear with diffuse necrotic debris, cell polymorphism, severe nuclear fragility, salt and pepper chromatin, and frequent mitoses, often atypical [<xref rid="REF12" ref-type="bibr">12</xref>]. Histology may show similar findings, including solid/organoid structure, abundant necrosis, abundant fibrous stroma, severe cell polymorphism, round-irregular shape, high nuclear/cytoplasm ratio, severe nuclear molding, salt and pepper chromatin, and frequent mitoses, often atypical. Immunohistochemistry may show CK +/- (dot-like), CgA +/-, Syn +, INSM1 +, SSTR2/5 -/+&#160;hormones, high or very high Ki67, diffuse positive or global loss of p53, or Rb global loss. Among these markers, ferritin is relatively non-specific. Nevertheless, studies have shown that in pancreatic and lung neuroendocrine neoplasms, SF can be a valuable tumor marker for bone metastases [<xref rid="REF27" ref-type="bibr">27</xref>,<xref rid="REF28" ref-type="bibr">28</xref>].</p><p>In normal prostate tissue, there are three types of epithelial cells: basal, luminal, and neuroendocrine. In prostate cancer, these cells can transdifferentiate into neuroendocrine-like cells in a process called NED&#160;[<xref rid="REF29" ref-type="bibr">29</xref>]. While the pathogenesis of NED remains poorly understood, synergistic physical interactions between the epithelial and neuroendocrine intraprostatic systems may be the main trigger [<xref rid="REF30" ref-type="bibr">30</xref>]. Unfortunately, NED correlates with disease progression and poor prognosis [<xref rid="REF31" ref-type="bibr">31</xref>,<xref rid="REF32" ref-type="bibr">32</xref>]. As with the neoplasms discussed above, hyperferritinemia is positively associated with prostate cancer risk, with each 100 ng/mL increase in the&#160;SF level increasing the odds ratio of prostate cancer by 1.20 (95% CI: 1.13-1.36) in a case-control study published in 2017 [<xref rid="REF33" ref-type="bibr">33</xref>].</p><p>In this case, bone marrow biopsy unexpectedly revealed poorly differentiated metastatic carcinoma with neuroendocrine differentiation. Typically, if malignancy were the cause for the patient&#8217;s elevated ferritin, we would have anticipated finding a primary hematologic neoplasm such as myelodysplastic syndrome or leukemia. There was little diagnostic clue that suggested neuroendocrine malignancy as the driving factor of the hyperferritinemia. The initial working diagnosis was metastatic prostate cancer that underwent neuroendocrine differentiation, as CT imaging revealed a severely enlarged prostate gland with sclerotic lesions at the pelvic bones without any other distinct masses. However, it is unclear whether the sclerotic bone lesions were from possible prostate cancer or another etiology completely. As the patient and family elected for hospice, further diagnostics such as prostate biopsy, PET/CT, and further lab testing such as LDH and PSA were unfortunately unable to be performed.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Ferritin is the protein that serves as the main mechanism for iron storage, as well as an acute-phase reactant, rising in response to acute or chronic inflammation, infection, injury, autoimmune disease, or malignancy. This case highlights the non-specific nature of ferritin elevation&#160;and the resulting broad differential diagnoses that its elevation entails. When evaluating ferritin levels, it is important to consider both iron storage and potential underlying conditions that could cause hyperferritinemia. Malignancy should be considered as part of the differential, especially when other common etiologies of hyperferritinemia have been considered and ruled out. Specifically, this case highlights the subtle presentation of NECs in the setting of an asymptomatic patient with a benign hematologic picture. Only upon bone marrow biopsy with follow-up imaging did the NEC of prostate origin with sclerotic bone lesions emerge as the leading differential.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Informed consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#160; Eugene S. Chao, Gene Yoshikawa, Charity Huang</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#160; Eugene S. Chao, Gene Yoshikawa, Xin Qing, Charity Huang</p><p><bold>Drafting of the manuscript:</bold>&#160; Eugene S. Chao</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#160; Gene Yoshikawa, Xin Qing, Charity Huang</p><p><bold>Supervision:</bold>&#160; Charity Huang</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Chemistry and biology of ferritin</article-title><source>Metallomics</source><person-group><name name-style="western"><surname>Plays</surname><given-names>M</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>S</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>R</given-names></name></person-group><volume>13</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/mtomcs/mfab021</pub-id><pub-id pub-id-type="pmcid">PMC8083198</pub-id><pub-id pub-id-type="pmid">33881539</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Ferritin for the clinician</article-title><source>Blood Rev</source><person-group><name name-style="western"><surname>Knovich</surname><given-names>MA</given-names></name><name name-style="western"><surname>Storey</surname><given-names>JA</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>LG</given-names></name><name name-style="western"><surname>Torti</surname><given-names>SV</given-names></name><name name-style="western"><surname>Torti</surname><given-names>FM</given-names></name></person-group><fpage>95</fpage><lpage>104</lpage><volume>23</volume><year>2009</year><pub-id pub-id-type="pmid">18835072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.blre.2008.08.001</pub-id><pub-id pub-id-type="pmcid">PMC2717717</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Serum ferritin during infection. A longitudinal study</article-title><source>Scand J Haematol</source><person-group><name name-style="western"><surname>Birgeg&#229;rd</surname><given-names>G</given-names></name><name name-style="western"><surname>H&#228;llgren</surname><given-names>R</given-names></name><name name-style="western"><surname>Killander</surname><given-names>A</given-names></name><name name-style="western"><surname>Str&#246;mberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Venge</surname><given-names>P</given-names></name><name name-style="western"><surname>Wide</surname><given-names>L</given-names></name></person-group><fpage>333</fpage><lpage>340</lpage><volume>21</volume><year>1978</year><pub-id pub-id-type="pmid">725531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-0609.1978.tb00374.x</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Ferritin - from iron, through inflammation and autoimmunity, to COVID-19</article-title><source>J Autoimmun</source><person-group><name name-style="western"><surname>Mahroum</surname><given-names>N</given-names></name><name name-style="western"><surname>Alghory</surname><given-names>A</given-names></name><name name-style="western"><surname>Kiyak</surname><given-names>Z</given-names></name><name name-style="western"><surname>Alwani</surname><given-names>A</given-names></name><name name-style="western"><surname>Seida</surname><given-names>R</given-names></name><name name-style="western"><surname>Alrais</surname><given-names>M</given-names></name><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group><fpage>102778</fpage><volume>126</volume><year>2022</year><pub-id pub-id-type="pmid">34883281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2021.102778</pub-id><pub-id pub-id-type="pmcid">PMC8647584</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Iron-binding proteins and risk of cancer in Taiwan</article-title><source>J Natl Cancer Inst</source><person-group><name name-style="western"><surname>Stevens</surname><given-names>RG</given-names></name><name name-style="western"><surname>Beasley</surname><given-names>RP</given-names></name><name name-style="western"><surname>Blumberg</surname><given-names>BS</given-names></name></person-group><fpage>605</fpage><lpage>610</lpage><volume>76</volume><year>1986</year><pub-id pub-id-type="pmid">3007843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/76.4.605</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Ferritin as an effective prognostic factor and potential cancer biomarker</article-title><source>Curr Issues Mol Biol</source><person-group><name name-style="western"><surname>Szymulewska-Konopko</surname><given-names>K</given-names></name><name name-style="western"><surname>Resze&#263;-Gie&#322;a&#380;yn</surname><given-names>J</given-names></name><name name-style="western"><surname>Ma&#322;eczek</surname><given-names>M</given-names></name></person-group><volume>47</volume><year>2025</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cimb47010060</pub-id><pub-id pub-id-type="pmcid">PMC11763953</pub-id><pub-id pub-id-type="pmid">39852175</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Nothing but NET: a review of neuroendocrine tumors and carcinomas</article-title><source>Neoplasia</source><person-group><name name-style="western"><surname>Oronsky</surname><given-names>B</given-names></name><name name-style="western"><surname>Ma</surname><given-names>PC</given-names></name><name name-style="western"><surname>Morgensztern</surname><given-names>D</given-names></name><name name-style="western"><surname>Carter</surname><given-names>CA</given-names></name></person-group><fpage>991</fpage><lpage>1002</lpage><volume>19</volume><year>2017</year><pub-id pub-id-type="pmid">29091800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2017.09.002</pub-id><pub-id pub-id-type="pmcid">PMC5678742</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Hindered submicron mobility and long-term storage of presynaptic dense-core granules revealed by single-particle tracking</article-title><source>Dev Neurobiol</source><person-group><name name-style="western"><surname>Scalettar</surname><given-names>BA</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>C</given-names></name><name name-style="western"><surname>Fulwiler</surname><given-names>A</given-names></name><name name-style="western"><surname>Prahl</surname><given-names>L</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A</given-names></name><name name-style="western"><surname>Hilken</surname><given-names>L</given-names></name><name name-style="western"><surname>Lochner</surname><given-names>JE</given-names></name></person-group><fpage>1181</fpage><lpage>1195</lpage><volume>72</volume><year>2012</year><pub-id pub-id-type="pmid">21976424</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/dneu.20984</pub-id><pub-id pub-id-type="pmcid">PMC3512567</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>The diagnosis and medical management of advanced neuroendocrine tumors</article-title><source>Endocr Rev</source><person-group><name name-style="western"><surname>Kaltsas</surname><given-names>GA</given-names></name><name name-style="western"><surname>Besser</surname><given-names>GM</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>AB</given-names></name></person-group><fpage>458</fpage><lpage>511</lpage><volume>25</volume><year>2004</year><pub-id pub-id-type="pmid">15180952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2003-0014</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Anemia of inflammation</article-title><source>Blood</source><person-group><name name-style="western"><surname>Weiss</surname><given-names>G</given-names></name><name name-style="western"><surname>Ganz</surname><given-names>T</given-names></name><name name-style="western"><surname>Goodnough</surname><given-names>LT</given-names></name></person-group><fpage>40</fpage><lpage>50</lpage><volume>133</volume><year>2019</year><pub-id pub-id-type="pmid">30401705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2018-06-856500</pub-id><pub-id pub-id-type="pmcid">PMC6536698</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases</article-title><source>Hepatology</source><person-group><name name-style="western"><surname>Bacon</surname><given-names>BR</given-names></name><name name-style="western"><surname>Adams</surname><given-names>PC</given-names></name><name name-style="western"><surname>Kowdley</surname><given-names>KV</given-names></name><name name-style="western"><surname>Powell</surname><given-names>LW</given-names></name><name name-style="western"><surname>Tavill</surname><given-names>AS</given-names></name></person-group><fpage>328</fpage><lpage>343</lpage><volume>54</volume><year>2011</year><pub-id pub-id-type="pmid">21452290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.24330</pub-id><pub-id pub-id-type="pmcid">PMC3149125</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms</article-title><source>Endocr Pathol</source><person-group><name name-style="western"><surname>Rindi</surname><given-names>G</given-names></name><name name-style="western"><surname>Mete</surname><given-names>O</given-names></name><name name-style="western"><surname>Uccella</surname><given-names>S</given-names></name><etal/></person-group><fpage>115</fpage><lpage>154</lpage><volume>33</volume><year>2022</year><pub-id pub-id-type="pmid">35294740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12022-022-09708-2</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?</article-title><source>Hum Pathol</source><person-group><name name-style="western"><surname>Bellizzi</surname><given-names>AM</given-names></name></person-group><fpage>8</fpage><lpage>33</lpage><volume>96</volume><year>2020</year><pub-id pub-id-type="pmid">31857137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.humpath.2019.12.002</pub-id><pub-id pub-id-type="pmcid">PMC7177196</pub-id></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis</article-title><source>Pediatr Blood Cancer</source><person-group><name name-style="western"><surname>Henter</surname><given-names>JI</given-names></name><name name-style="western"><surname>Horne</surname><given-names>A</given-names></name><name name-style="western"><surname>Aric&#243;</surname><given-names>M</given-names></name><etal/></person-group><fpage>124</fpage><lpage>131</lpage><volume>48</volume><year>2007</year><pub-id pub-id-type="pmid">16937360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pbc.21039</pub-id></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Causes and significance of markedly elevated serum ferritin levels in an academic medical center</article-title><source>J Clin Rheumatol</source><person-group><name name-style="western"><surname>Moore C</surname><given-names>Jr</given-names></name><name name-style="western"><surname>Ormseth</surname><given-names>M</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>H</given-names></name></person-group><fpage>324</fpage><lpage>328</lpage><volume>19</volume><year>2013</year><pub-id pub-id-type="pmid">23965472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/RHU.0b013e31829ce01f</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Strength in numbers: identifying a significant association between high serum ferritin levels and newly diagnosed malignancy in a large health organization cohort</article-title><source>Cancer Epidemiol Biomarkers Prev</source><person-group><name name-style="western"><surname>Gesher</surname><given-names>AS</given-names></name><name name-style="western"><surname>Grinin</surname><given-names>K</given-names></name><name name-style="western"><surname>Atias</surname><given-names>D</given-names></name><name name-style="western"><surname>Patalon</surname><given-names>T</given-names></name><name name-style="western"><surname>Gazit</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoshen</surname><given-names>M</given-names></name><name name-style="western"><surname>Dagan</surname><given-names>A</given-names></name></person-group><fpage>190</fpage><lpage>196</lpage><volume>34</volume><year>2025</year><pub-id pub-id-type="pmid">39445830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1055-9965.EPI-24-0757</pub-id></element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome</article-title><source>Blood</source><person-group><name name-style="western"><surname>Sanz</surname><given-names>G</given-names></name><name name-style="western"><surname>Nomdedeu</surname><given-names>B</given-names></name><name name-style="western"><surname>Such</surname><given-names>E</given-names></name><etal/></person-group><fpage>640</fpage><volume>112</volume><year>2008</year></element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia: a YACHT multicenter retrospective study</article-title><source>Clin Lymphoma Myeloma Leuk</source><person-group><name name-style="western"><surname>Tachibana</surname><given-names>T</given-names></name><name name-style="western"><surname>Andou</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>M</given-names></name><etal/></person-group><fpage>415</fpage><lpage>421</lpage><volume>18</volume><year>2018</year><pub-id pub-id-type="pmid">29673622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clml.2018.03.009</pub-id></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Iron overload in children with acute lymphoblastic and acute myeloblastic leukemia-experience of one center</article-title><source>Cancers (Basel)</source><person-group><name name-style="western"><surname>Sawicka-Zukowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Kretowska-Grunwald</surname><given-names>A</given-names></name><name name-style="western"><surname>Kania</surname><given-names>A</given-names></name><etal/></person-group><fpage>367</fpage><volume>16</volume><year>2024</year><pub-id pub-id-type="pmid">38254856</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16020367</pub-id><pub-id pub-id-type="pmcid">PMC10814127</pub-id></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>Serum ferritin, vitamin D and pathological factors in breast cancer patients</article-title><source>Med J Islam Repub Iran</source><person-group><name name-style="western"><surname>Fadavi</surname><given-names>P</given-names></name><name name-style="western"><surname>Nafisi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hariri</surname><given-names>R</given-names></name><etal/></person-group><fpage>162</fpage><volume>35</volume><year>2021</year><pub-id pub-id-type="pmid">35465166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.47176/mjiri.35.162</pub-id><pub-id pub-id-type="pmcid">PMC8985634</pub-id></element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Prognostic role of pretreatment serum ferritin concentration in lung cancer patients: a meta-analysis</article-title><source>World J Clin Cases</source><person-group><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ge</surname><given-names>JT</given-names></name></person-group><fpage>12230</fpage><lpage>12239</lpage><volume>10</volume><year>2022</year><pub-id pub-id-type="pmid">36483825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12998/wjcc.v10.i33.12230</pub-id><pub-id pub-id-type="pmcid">PMC9724546</pub-id></element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Serum ferritin in colorectal cancer patients and its prognostic evaluation</article-title><source>Int J Biol Markers</source><person-group><name name-style="western"><surname>Lorenzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Lorenzi</surname><given-names>B</given-names></name><name name-style="western"><surname>Vernillo</surname><given-names>R</given-names></name></person-group><fpage>235</fpage><lpage>241</lpage><volume>21</volume><year>2006</year><pub-id pub-id-type="pmid">17177162</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/172460080602100407</pub-id></element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Prognostic role of pre-operative serum ferritin level in stage 2 colon cancer</article-title><source>Eur Rev Med Pharmacol Sci</source><person-group><name name-style="western"><surname>Demir</surname><given-names>H</given-names></name><name name-style="western"><surname>Beypinar</surname><given-names>I</given-names></name><name name-style="western"><surname>Urvay</surname><given-names>S</given-names></name><name name-style="western"><surname>Davarc&#305;</surname><given-names>SE</given-names></name><name name-style="western"><surname>Baykara</surname><given-names>M</given-names></name></person-group><fpage>6473</fpage><lpage>6479</lpage><volume>25</volume><year>2021</year><pub-id pub-id-type="pmid">34787851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202111_27091</pub-id></element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Prognostic value of international normalized ratio-to-albumin ratio and ferritin level in chronic liver patients with hepatocellular carcinoma</article-title><source>J Gastrointest Cancer</source><person-group><name name-style="western"><surname>&#220;lger</surname><given-names>Y</given-names></name><name name-style="western"><surname>Delik</surname><given-names>A</given-names></name></person-group><fpage>1028</fpage><lpage>1033</lpage><volume>53</volume><year>2022</year><pub-id pub-id-type="pmid">34786643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12029-021-00738-3</pub-id></element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Serum ferritin and the risk of hepatocellular carcinoma in chronic liver disease of viral etiology: a case-control study</article-title><source>Indian J Gastroenterol</source><person-group><name name-style="western"><surname>Patil</surname><given-names>PS</given-names></name><name name-style="western"><surname>Mohandas</surname><given-names>KM</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>SA</given-names></name></person-group><fpage>12</fpage><lpage>18</lpage><volume>33</volume><year>2014</year><pub-id pub-id-type="pmid">24006121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12664-013-0367-5</pub-id></element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>The crucial value of serum ferritin in assessing high-risk factors and prognosis for patients with endometrial carcinoma</article-title><source>BMC Womens Health</source><person-group><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>B</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S</given-names></name><name name-style="western"><surname>Mu</surname><given-names>X</given-names></name></person-group><fpage>415</fpage><volume>23</volume><year>2023</year><pub-id pub-id-type="pmid">37550644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12905-023-02575-x</pub-id><pub-id pub-id-type="pmcid">PMC10408112</pub-id></element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Role of selected circulating tumor biomarkers in patients with skeletal metastatic pancreatic neuroendocrine neoplasms</article-title><source>J Clin Med</source><person-group><name name-style="western"><surname>Rosiek</surname><given-names>V</given-names></name><name name-style="western"><surname>Janas</surname><given-names>K</given-names></name><name name-style="western"><surname>Witkowska</surname><given-names>M</given-names></name><name name-style="western"><surname>Kos-Kud&#322;a</surname><given-names>B</given-names></name></person-group><fpage>4687</fpage><volume>12</volume><year>2023</year><pub-id pub-id-type="pmid">37510802</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12144687</pub-id><pub-id pub-id-type="pmcid">PMC10380808</pub-id></element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Serum tumor markers for detection of bone metastases in patients with lung neuroendocrine neoplasms</article-title><source>Cancer Treat Res Commun</source><person-group><name name-style="western"><surname>Rosiek</surname><given-names>V</given-names></name><name name-style="western"><surname>W&#243;jcik-Giertuga</surname><given-names>M</given-names></name><name name-style="western"><surname>Kos-Kud&#322;a</surname><given-names>B</given-names></name></person-group><fpage>100533</fpage><volume>31</volume><year>2022</year><pub-id pub-id-type="pmid">35202905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ctarc.2022.100533</pub-id></element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure</article-title><source>Front Oncol</source><person-group><name name-style="western"><surname>Hu</surname><given-names>CD</given-names></name><name name-style="western"><surname>Choo</surname><given-names>R</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name></person-group><fpage>90</fpage><volume>5</volume><year>2015</year><pub-id pub-id-type="pmid">25927031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2015.00090</pub-id><pub-id pub-id-type="pmcid">PMC4396194</pub-id></element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Neuroendocrine differentiation in prostate cancer: from lab to bedside</article-title><source>Urol Int</source><person-group><name name-style="western"><surname>Cindolo</surname><given-names>L</given-names></name><name name-style="western"><surname>Cantile</surname><given-names>M</given-names></name><name name-style="western"><surname>Vacherot</surname><given-names>F</given-names></name><name name-style="western"><surname>Terry</surname><given-names>S</given-names></name><name name-style="western"><surname>de la Taille</surname><given-names>A</given-names></name></person-group><fpage>287</fpage><lpage>296</lpage><volume>79</volume><year>2007</year><pub-id pub-id-type="pmid">18025844</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000109711</pub-id></element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="journal"><article-title>The neuroendocrine phenotype in prostate cancer: basic and clinical aspects</article-title><source>J Endocrinol Invest</source><person-group><name name-style="western"><surname>Mosca</surname><given-names>A</given-names></name><name name-style="western"><surname>Berruti</surname><given-names>A</given-names></name><name name-style="western"><surname>Russo</surname><given-names>L</given-names></name><name name-style="western"><surname>Torta</surname><given-names>M</given-names></name><name name-style="western"><surname>Dogliotti</surname><given-names>L</given-names></name></person-group><fpage>141</fpage><lpage>145</lpage><volume>28</volume><year>2005</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/16625864/">https://pubmed.ncbi.nlm.nih.gov/16625864/</uri><pub-id pub-id-type="pmid">16625864</pub-id></element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><person-group><name name-style="western"><surname>Krauss</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hayek</surname><given-names>S</given-names></name><name name-style="western"><surname>Amin</surname><given-names>M</given-names></name><etal/></person-group><fpage>0</fpage><lpage>25</lpage><volume>81</volume><year>2011</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijrobp.2010.12.064</pub-id><pub-id pub-id-type="pmid">21596486</pub-id></element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer</article-title><source>Oncotarget</source><person-group><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>An</surname><given-names>P</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J</given-names></name><etal/></person-group><fpage>17862</fpage><lpage>17872</lpage><volume>8</volume><year>2017</year><pub-id pub-id-type="pmid">28160568</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.14977</pub-id><pub-id pub-id-type="pmcid">PMC5392292</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>